Scarica l'app Stockscreener
8.43
0.36%
0.03
Dopo l'orario di chiusura:
8.38
-0.05
-0.59%
Precedente Chiudi:
$8.40
Aprire:
$8.24
Volume 24 ore:
14,563
Relative Volume:
0.12
Capitalizzazione di mercato:
$44.59M
Reddito:
$858.00K
Utile/perdita netta:
$-8.98M
Rapporto P/E:
-40.94
EPS:
-0.2059
Flusso di cassa netto:
$-29.81M
1 W Prestazione:
-0.12%
1M Prestazione:
-23.15%
6M Prestazione:
+105.97%
1 anno Prestazione:
+81.68%
Intervallo 1D:
$8.20
$8.45
Intervallo di 1 settimana:
$7.90
$9.245
Portata 52W:
$1.7608
$11.49
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
8.43 | 44.59M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-10 | Iniziato | Wedbush | Outperform |
| 2022-12-09 | Iniziato | JP Morgan | Overweight |
| 2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-08-23 | Iniziato | Cowen | Outperform |
| 2021-08-23 | Iniziato | Evercore ISI | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - TipRanks
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - MarketScreener
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio (NASDAQ: RLYB) plans Candid merger, $505.5M financing and CVR structure - Stock Titan
Rallybio: Net loss improved to $9.0 million in 2025 amid a pending merger, asset sale, and cost reductions - TradingView
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Candid Merging Into Public Market - San Diego Business Journal
RLYB Q4'25 Earnings: EPS estimate is (1.24) USD - TradingView
Retail Surge: Will Rallybio Corporation benefit from current market trendsNew Guidance & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Energy Moves: Can Rallybio Corporation generate free cash flowJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves - TipRanks
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - PR Newswire
Geopolitics Watch: Whats the profit margin of Rallybio CorporationWeekly Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $40.00 - Defense World
Rallybio (RLYB) Expected to Announce Earnings on Thursday - MarketBeat
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation – RLYB - Weekly Voice
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio - Wilson Sonsini
Rallybio and Candid Therapeutics To Merge - citybiz
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):